^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Ruxience (rituximab-pvvr) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/01/2020
Excerpt:
Ruxience in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL.
Secondary therapy:
Chemotherapy
